NSE · JFLLIFE
JFL Life Sciences Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹82 Cr with net profit ₹4 Cr — a 5.07% net margin, versus 7.01% the period before.
Shareholding
As of 2026-06-30
- Promoter67.47%
- Public32.53%
943 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.78× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #1 of 50 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,319 Cr | 84.56 | 22.04 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,933 Cr | 160.96 | 9.52 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,520 Cr | 113.07 | 4 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹24,811 Cr | 100.55 | 19.25 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,279 Cr | 113.33 | 5.37 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,056 Cr | 66.76 | 4.88 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,793 Cr | 50.54 | 4.55 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,719 Cr | 28.05 | 3.88 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹5,952 Cr | 47.1 | 6.38 | 12.36% | 18.59% |
| Bliss GVS Pharma Ltd. | ₹4,827 Cr | 141.35 | 4.04 | 8.95% | 11.15% |
| JFL Life Sciences Limited(this company) | — | 25.9 | 0.93 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashJFL Life Sciences Limited is listed on the Indian markets with a market capitalization of Rs 36 Cr. The company reported revenue of Rs 82.05 Cr and a profit margin of 487.1%. Its EPS stands at 1.94, and the stock is trading at a P/E of 22.
Positives
- +The profit margin of 487.1% is positive.
- +The debt-to-equity ratio is 0.22, indicating low leverage.
- +Promoter shareholding is substantial at 67.4681% as of June 30, 2026.
- +Revenue increased to Rs 82.0524 Cr in Mar 2025 from Rs 47.0615 Cr in Mar 2024.
- +Net profit increased to Rs 4.1586 Cr in Mar 2025 from Rs 3.3004 Cr in Mar 2024.
Negatives
- −No quarterly EPS figures are available in the provided data.
- −No information is provided regarding dividend yield.
- −No FII or DII presence in the shareholding as of June 30, 2026.
Financial performance
JFL Life Sciences Limited's revenue increased to Rs 82.05 Cr in Mar 2025 from Rs 47.0615 Cr in Mar 2024. Net profit also rose to Rs 4.1586 Cr in Mar 2025 from Rs 3.3004 Cr in Mar 2024. The company's EPS was 1.26 in Mar 2025, an increase from 1.0 in Mar 2024.
Profitability & returns
The company reported a return on equity (ROE) of 13.96% and a return on capital employed (ROCE) of 15.8363%. The profit margin for JFL Life Sciences Limited is 487.1%. EPS in Mar 2025 was 1.26, and in Mar 2024 it was 1.0.
Balance sheet
JFL Life Sciences Limited has a debt-to-equity ratio of 0.22. The book value per share is Rs 13.9. There are no figures provided for total assets or liabilities.
Ownership & pledges
As of June 30, 2026, promoters held 67.4681% of the shares, while public shareholding was 32.5319%. There was no FII or DII holding. The promoter shareholding has remained constant at 67.4681% since September 30, 2022. No shares are reported as pledged.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.